TY - JOUR
T1 - KS-EMPD-1
T2 - a novel cell line of primary extramammary Paget’s disease
AU - Ito, Takamichi
AU - Tanaka, Yuka
AU - Ichiki, Toshio
AU - Kaku-Ito, Yumiko
AU - Nakahara, Takeshi
N1 - Publisher Copyright:
© 2023, The Author(s) under exclusive licence to Japan Human Cell Society.
PY - 2023/9
Y1 - 2023/9
N2 - Extramammary Paget’s disease (EMPD) is a rare skin cancer that mainly occurs in apocrine sweat gland-rich areas in elderly people. The prognosis of metastatic EMPD is unfavorable because of the lack of fully effective systemic therapies. However, the difficulty in establishing a model of EMPD has hampered basic research for exploring its pathogenesis and optimal treatments. Here, we established for the first time an EMPD cell line (named KS-EMPD-1) from a primary tumor on the left inguinal region of an 86-year-old Japanese male. The cells were successfully maintained for more than 1 year, with a doubling time of 31.2 ± 0.471 h. KS-EMPD-1 exhibited constant growth, spheroid formation, and invasiveness, and was confirmed to be identical to the original tumor by short tandem repeat analyses, whole exome sequencing, and immunohistochemistry (CK7+CK20−GCDFP15+). Western blotting of the cells revealed the protein expression of HER2, NECTIN4, and TROP2, which have recently attracted attention as potential therapeutic targets for EMPD. KS-EMPD-1 was highly sensitive to docetaxel and paclitaxel on chemosensitivity test. The KS-EMPD-1 cell line is a promising resource for basic and preclinical research on EMPD to better define the tumor characteristics and treatment strategy of this rare cancer.
AB - Extramammary Paget’s disease (EMPD) is a rare skin cancer that mainly occurs in apocrine sweat gland-rich areas in elderly people. The prognosis of metastatic EMPD is unfavorable because of the lack of fully effective systemic therapies. However, the difficulty in establishing a model of EMPD has hampered basic research for exploring its pathogenesis and optimal treatments. Here, we established for the first time an EMPD cell line (named KS-EMPD-1) from a primary tumor on the left inguinal region of an 86-year-old Japanese male. The cells were successfully maintained for more than 1 year, with a doubling time of 31.2 ± 0.471 h. KS-EMPD-1 exhibited constant growth, spheroid formation, and invasiveness, and was confirmed to be identical to the original tumor by short tandem repeat analyses, whole exome sequencing, and immunohistochemistry (CK7+CK20−GCDFP15+). Western blotting of the cells revealed the protein expression of HER2, NECTIN4, and TROP2, which have recently attracted attention as potential therapeutic targets for EMPD. KS-EMPD-1 was highly sensitive to docetaxel and paclitaxel on chemosensitivity test. The KS-EMPD-1 cell line is a promising resource for basic and preclinical research on EMPD to better define the tumor characteristics and treatment strategy of this rare cancer.
KW - Antibody–drug conjugate
KW - Cell line
KW - NECTIN4
KW - Skin cancer
KW - TROP2
UR - http://www.scopus.com/inward/record.url?scp=85166383000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166383000&partnerID=8YFLogxK
U2 - 10.1007/s13577-023-00951-1
DO - 10.1007/s13577-023-00951-1
M3 - Article
C2 - 37432591
AN - SCOPUS:85166383000
SN - 0914-7470
VL - 36
SP - 1813
EP - 1829
JO - Human Cell
JF - Human Cell
IS - 5
ER -